Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Cahaba Pharmaceuticals
Description1% uracil topical
Molecular Target Dihydropyrimidine dehydrogenase
Mechanism of ActionDihydropryimidine dehydrogenase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationHand-foot syndrome
Indication DetailsTreat hand-foot syndrome
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today